BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29243019)

  • 1. Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients.
    Umeda T; Koizumi M; Fukai S; Miyaji N; Motegi K; Nakazawa S; Takiguchi T
    Ann Nucl Med; 2018 Feb; 32(2):105-113. PubMed ID: 29243019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bone metastasis burden as an imaging biomarker by quantitative single-photon emission computed tomography/computed tomography for assessing prostate cancer with bone metastasis: a phantom and clinical study.
    Motegi K; Matsutomo N; Yamamoto T; Koizumi M
    Radiol Phys Technol; 2020 Sep; 13(3):219-229. PubMed ID: 32535819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
    Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
    Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response.
    Roque V; Jessop M; Pereira L; Gape P; Dizdarevic S; Sousa E; Carolino E
    Nucl Med Commun; 2019 Jun; 40(6):588-596. PubMed ID: 30908340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New index to assess the extent of bone disease in patients with prostate cancer using SPECT/CT.
    Ichikawa H; Shibutani T; Onoguchi M; Taniguchi Y
    Ann Nucl Med; 2022 Nov; 36(11):941-950. PubMed ID: 36048347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
    Anand A; Morris MJ; Kaboteh R; Båth L; Sadik M; Gjertsson P; Lomsky M; Edenbrandt L; Minarik D; Bjartell A
    J Nucl Med; 2016 Jan; 57(1):41-5. PubMed ID: 26315832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of
    Oya T; Ichikawa Y; Nakamura S; Tomita Y; Sasaki T; Inoue T; Sakuma H
    Ann Nucl Med; 2023 Jun; 37(6):360-370. PubMed ID: 36947324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods.
    Takahashi Y; Yoshimura M; Suzuki K; Hashimoto T; Hirose H; Uchida K; Inoue S; Koizumi K; Tokuuye K
    Ann Nucl Med; 2012 Aug; 26(7):586-93. PubMed ID: 22744807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer.
    Reza M; Kaboteh R; Sadik M; Bjartell A; Wollmer P; Trägårdh E
    BMC Med Imaging; 2018 May; 18(1):8. PubMed ID: 29728144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases.
    Tabotta F; Jreige M; Schaefer N; Becce F; Prior JO; Nicod Lalonde M
    BMC Musculoskelet Disord; 2019 Dec; 20(1):619. PubMed ID: 31878904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
    Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
    Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
    Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
    Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bone scan index change over time on automated calculation in bone scintigraphy.
    Shintawati R; Achmad A; Higuchi T; Shimada H; Hirasawa H; Arisaka Y; Takahashi A; Nakajima T; Tsushima Y
    Ann Nucl Med; 2015 Dec; 29(10):911-20. PubMed ID: 26373556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of skeletal standardized uptake values obtained by quantitative single-photon emission computed tomography-computed tomography in differential diagnosis of bone metastases.
    Zhang Y; Li B; Yu H; Song J; Zhou Y; Shi H
    Nucl Med Commun; 2021 Jan; 42(1):63-67. PubMed ID: 33044406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
    Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
    Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.